Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 6
2006 1
2007 1
2008 5
2009 4
2010 3
2011 2
2012 2
2013 6
2014 4
2015 4
2016 4
2017 8
2018 4
2019 5
2020 2
2021 6
2022 5
2023 8
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.
Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, Ammerlaan AJC, Boer JM, Beverloo HB, Sleight B, Chen Y, Vormoor-Bürger B, Rives S, Bielorai B, Rössig C, Petit A, Rizzari C, Engstler G, Starý J, Bautista Sirvent FJ, Chen-Santel C, Bruno B, Bertrand Y, Rialland F, Plat G, Reinhardt D, Vinti L, Von Stackelberg A, Locatelli F, Zwaan CM. Pennesi E, et al. Among authors: boer jm. Leukemia. 2022 Jun;36(6):1516-1524. doi: 10.1038/s41375-022-01576-3. Epub 2022 Apr 25. Leukemia. 2022. PMID: 35468945 Free PMC article. Clinical Trial.
Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.
Langenberg KPS, Meister MT, Bakhuizen JJ, Boer JM, van Eijkelenburg NKA, Hulleman E, Ilan U, Looze EJ, Dierselhuis MP, van der Lugt J, Breunis W, Schild LG, Ober K, van Hooff SR, Scheijde-Vermeulen MA, Hiemcke-Jiwa LS, Flucke UE, Kranendonk MEG, Wesseling P, Sonneveld E, Punt S, Boltjes A, van Dijk F, Verwiel ETP, Volckmann R, Hehir-Kwa JY, Kester LA, Koudijs MMJ, Waanders E, Holstege FCP, Vormoor HJ, Hoving EW, van Noesel MM, Pieters R, Kool M, Stumpf M, Blattner-Johnson M, Balasubramanian GP, Van Tilburg CM, Jones BC, Jones DTW, Witt O, Pfister SM, Jongmans MCJ, Kuiper RP, de Krijger RR, Wijnen MHW, den Boer ML, Zwaan CM, Kemmeren P, Koster J, Tops BBJ, Goemans BF, Molenaar JJ. Langenberg KPS, et al. Among authors: boer jm. Eur J Cancer. 2022 Nov;175:311-325. doi: 10.1016/j.ejca.2022.09.001. Epub 2022 Sep 29. Eur J Cancer. 2022. PMID: 36182817 Free PMC article.
Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression.
Molina O, Ortega-Sabater C, Thampi N, Fernández-Fuentes N, Guerrero-Murillo M, Martínez-Moreno A, Vinyoles M, Velasco-Hernández T, Bueno C, Trincado JL, Granada I, Campos D, Giménez C, Boer JM, den Boer ML, Calvo GF, Camós M, Fuster JL, Velasco P, Ballerini P, Locatelli F, Mullighan CG, Spierings DCJ, Foijer F, Pérez-García VM, Menéndez P. Molina O, et al. Among authors: boer jm. EMBO Mol Med. 2024 Jan;16(1):64-92. doi: 10.1038/s44321-023-00006-w. Epub 2023 Dec 15. EMBO Mol Med. 2024. PMID: 38177531 Free PMC article.
Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
Kroeze E, Iaccarino I, Kleisman MM, Mondal M, Beder T, Khouja M, Höppner MP, Scheijde-Vermeulen MA, Kester LA, Brüggemann M, Baldus CD, Cario G, Bladergroen RS, Garnier N, Attarbaschi A, Verdu-Amorós J, Sutton R, Macintyre EA, Scholten K, Arias Padilla L, Burkhardt B, Beishuizen A, den Boer ML, Kuiper RP, Loeffen JLC, Boer JM, Klapper W. Kroeze E, et al. Among authors: boer jm. Blood. 2024 Apr 8:blood.2024023938. doi: 10.1182/blood.2024023938. Online ahead of print. Blood. 2024. PMID: 38588489
The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia.
Østergaard A, Enshaei A, Pieters R, Vora A, Horstmann MA, Escherich G, Johansson B, Heyman M, Schmiegelow K, Hoogerbrugge PM, den Boer ML, Kuiper RP, Moorman AV, Boer JM, van Leeuwen FN. Østergaard A, et al. Among authors: boer jm. Hemasphere. 2023 May 4;7(5):e875. doi: 10.1097/HS9.0000000000000875. eCollection 2023 May. Hemasphere. 2023. PMID: 37153875 Free PMC article.
Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement.
Kroeze E, Arias Padilla L, Bakker M, Boer JM, Hagleitner MM, Burkhardt B, Mori T, Attarbaschi A, Verdú-Amorós J, Pillon M, Anderzhanova L, Kabíčková E, Chiang AKS, Kebudi R, Mellgren K, Lazic J, Jazbec J, Meijerink JPP, Beishuizen A, Loeffen JLC;   European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the International Berlin–Frankfurt–Münster (i-BFM) Study. Kroeze E, et al. Among authors: boer jm. Cancers (Basel). 2022 Aug 12;14(16):3895. doi: 10.3390/cancers14163895. Cancers (Basel). 2022. PMID: 36010889 Free PMC article.
The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis.
Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, Winterberg D, Mary C, Corallo F, Taurelle J, Narbeburu E, Neyton SL, Déramé M, Pengam S, Vogiatzi F, Bornhauser B, Bourquin JP, Raffel S, Dovhan V, Schüler T, Escherich G, den Boer ML, Boer JM, Wessels W, Peipp M, Alten J, Antić Ž, Bergmann AK, Schrappe M, Cario G, Brüggemann M, Poirier N, Schewe DM. Lenk L, et al. Among authors: boer jm. Blood. 2024 Mar 22:blood.2023021088. doi: 10.1182/blood.2023021088. Online ahead of print. Blood. 2024. PMID: 38518105 Free article.
75 results